| Drug General Information |
| Drug ID |
D0RV7J
|
| Former ID |
DIB014987
|
| Drug Name |
RG-7256
|
| Synonyms |
B-raf inhibitor (melanoma), Roche/Plexxikon
|
| Indication |
Melanoma [ICD9: 172; ICD10:C43]
|
Discontinued in Phase 1 |
[1]
|
|---|
| Company |
Roche Holding AG
|
| Target and Pathway |
| Target(s) |
B-Raf proto-oncogene serine/threonine-protein kinase |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
FoxO signaling pathway
|
|
mTOR signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Focal adhesion
|
|
Natural killer cell mediated cytotoxicity
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Serotonergic synapse
|
|
Long-term depression
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Alcoholism
|
|
Hepatitis C
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Thyroid cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
IL-7 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Integrin signalling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
CDC42 signaling events
|
|
mTOR signaling pathway
|
|
Ras signaling in the CD4+ TCR pathway
|
|
ErbB1 downstream signaling
|
|
PDGFR-beta signaling pathway
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
Spry regulation of FGF signaling
|
|
Frs2-mediated activation
|
|
ARMS-mediated activation
|
|
CREB phosphorylation through the activation of Ras
|
|
RAF activation
|
|
MAP2K and MAPK activation
|
|
Negative feedback regulation of MAPK pathway
|
|
Negative regulation of MAPK pathway
|
|
WikiPathways
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
Estrogen signaling pathway
|
|
Senescence and Autophagy in Cancer
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
Focal Adhesion
|
|
Bladder Cancer
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Polycystic Kidney Disease Pathway
|
|
Corticotropin-releasing hormone
|
|
B Cell Receptor Signaling Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by FGFR
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Integrin-mediated Cell Adhesion
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022593) |
|---|
| REF 2 | First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol. 2015 Aug 27. |
|---|
